STIC-ILL

From:

Hunt, Jennifer

Sent: To:

Wednesday, October 31, 2001 2:54 PM

STIC-ILL

Subject:

References for 09/186,475

Please send me the following references ASAP:

Proc Annu Meet Am Soc Clin Oncol, (1998). Vol. 17, pp. A843

SU5416: A potent and selective Flk-1/KDR kinase inhibitor that blocks receptor autophosphorylation, endothelial cell mitogenesis, and tumor growth, by Tang, Cho; Li, Sun; Tran, Jade; Liang, Chris; Nematalla, Asaad; Fong, Annie; App, Harald; Rice, Audie; Kim, Young; Schreck, Randy; Chen, Jason; Dowd, Brian; Suto, Eric; Vasile, Steve; Shawver, Laura; McMahon, Jerry; Hirth, Peter

Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-205 Publisher: American

Chemical Society, Washington, D. C. CODEN: 65QTAA DT Conference; Meeting Abstract

Proceedings of the American Association for Cancer Research Annual Meeting, (March, 1998) Vol. 39, pp. 96

Expert Opinion on Investigational Drugs, (1998) 7/6 (1015-1021)

NEOPLASIA, (1999 Apr) 1 (1) 31-41

Proc Annu Meet Am Soc Clin Oncol, (1999). Vol. 18, pp. A618

Proc Annu Meet Am Soc Clin Oncol, (1999). Vol. 18, pp. A619

Thanks,

Jennifer Hunt Patent Examiner, Art Unit 1642 CM1-8D06 (mailbox 8E12) (703)308-7548

STIC-L

From: Sent: To: Subjec Hunt, Jennifer Wednesday, October 31, 2001 2:54 PM STIC-ILL References for 09/186,475

Please send me the following references ASAP:

Proc Annu Meet Am Soc Clin Oncol, (1998). Vol. 17, pp. A843

SU5416: A potent and selective Flk-1/KDR kinase inhibitor that blocks receptor autophosphorylation, endothelial cell mitogenesis, and tumor growth, by Tang, Cho; Li, Sun; Tran, Jade; Liang, Chris; Nematalla, Asaad; Fong, Annie; App, Harald; Rice, Audie; Kim, Young; Schreck, Randy; Chen, Jason; Dowd, Brian; Suto, Eric; Vasile, Steve; Shawver, Laura; McMahon, Jerry; Hirth, Peter

Book of Abstracts, 215th ACS National Meeting, Dallas, March 29-April 2 (1998), MEDI-205 Publisher: American Chemical Society, Washington, D. C. CODEN: 65QTAA DT Conference; Meeting Abstract

Proceedings of the American Association for Cancer Research Annual Meeting (March, 1998) Vol. 39, pp. 96. Scientific and Technical Scientific and

Expert Opinion on Investigational Drugs, (1998) 7/6 (1015-1021)

NEOPLASIA, (1999 Apr) 1 (1) 31-41

Proc Annu Meet Am Soc Clin Oncol, (1999). Vol. 18, pp. A618

Proc Annu Meet Am Soc Clin Oncol, (1999). Vol. 18, pp. A619

Thanks,

Jennifer Hunt Patent Examiner, Art Unit 1642 CM1-8D06 (mailbox 8E12) (703)308-7548

Information Center NOV 0 2 RECD MW.

& T.M. OFFICE

10935468

(FILE 'HOME' ENTERED AT 14:10:18 ON 31 OCT 2001)

FILE 'REGISTRY' ENTERED AT 14:10:39 ON 31 OCT 2001

E SU 5416/CN

L1 1 S E3

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS, CANCERLIT, SCISEARCH, TOXLINE' ENTERED AT 14:11:54 ON 31 OCT 2001

L2 3814153 S DOSE OR DOSAGE

L3 10128 S STANDARD CURVE

L4 205 S L2 (10A) L3

L5 85 DUP REM L4 (120 DUPLICATES REMOVED)

L6 3411221 S MARKER OR RECEPTOR OR FLK-1 OR PHOSPHORYLAT####

L7 4 S L5 (P) L6

L8 120189 S ANGIOGENESIS OR VASCULARIZ#####

L9 0 S L4 (P) L8

L10 385 S SU5416 OR SU 5416

L11 119 S L10 (P) L8

L12 51 DUP REM L11 (68 DUPLICATES REMOVED)

L13 7 S L12 (P) L2

L14 32 S L12 (P) L6

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS

RN 204005-46-9 REGISTRY

CN 2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN SU 5416

FS 3D CONCORD

MF C15 H14 N2 O

SR CA

LC STN Files: BIOSIS, CA, CAPLUS, DRUGPAT, DRUGUPDATES, TOXLIT, USPATFULL

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

37 REFERENCES IN FILE CA (1967 TO DATE)

37 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L7 ANSWER 1 OF 4 MEDLINE

AN 84058724 MEDLINE

DN 84058724 PubMed ID: 6642076

TI A new in vitro melanophore bioassay for MSH using tail-fins of Xenopus tadpoles.

AU de Graan P N; Molenaar R; van de Veerdonk F C

SO MOLECULAR AND CELLULAR ENDOCRINOLOGY, (1983 Oct) 32 (2-3) 271-84. Journal code: E69; 7500844. ISSN: 0303-7207.

CY Netherlands

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 198401

ED Entered STN: 19900319

Last Updated on STN: 19900319

Entered Medline: 19840107

AB . . . obtained with alpha-MSH is sigmoidal with a linear portion between 0.5 and 2.0 ng alpha-MSH/ml. In this range, the log dose -response curve can be used as the standard curve in a bioassay for melanotropic activity, applying either the melanophore index (assay I) or a photometric transmittance measurement (assay II). . . chromatophores; (2) to date it is the only system suitable for photoaffinity labelling of alpha-MSH receptors; and (3) the melanophore receptor requirements differ from those of Rana.

Error Er Definition rs		0	0 0
Defini			
Stamp	2001/10/3 1 14:13		2001/10/3 1 14:14
DBs	USPA T; US-P GPUB; JPO; UPEW ENT; IBM		USPA T; US-P GPUB; JPO; JPO; DERW ENT; IBM
Search Text	or dosage		ırd adj1 curve
	dose		4 standard
L # Hits	L1 24083		L2 8474
Type]	BRS	_	BRS
			~

		:		
Er ro rs	0	0	0	
Error Definition				
Comment s				
Time Stamp	2001/10/3 1 14:16	2001/10/3 1 14:16	2001/10/3 1 14:16	
DBs	USPA T; US-P GPUB ; JPO; JPO; DERW ENT; IBM	USPA T; US-P GPUB; JPO; JPO; DERW ENT; IBM	USPA T; US-P GPUB ; JPO; JPO; DERW ENT; IBM	
Search Text	angiogenesis or vasculariz\$5	3 same 4	1 same 2 same 4	
Hits	7995	0	0	
г#	L4	1.5	L 6	
Туре	BRS 1	BRS	BRS	
	4	ഗ	9	

Туре	#	Hits	Search Text	DBs	Time Stamp	Comment	Error Definition	H H H
BRS	L7	17129	marker or receptor or flk-1 or phosphorylat\$4	USPA T; US-P GPUB ; JPO; DERW ENT; IBM	2001/10/3 1 14:19			0
BRS	L8	4	3 same 7	USPA T; US-P GPUB ; JPO; JPO; JERW ENT; IBM	2001/10/3 1 14:22			0
BRS	6 L	16	(su adjl "5416") or su5416	USPA T; US-P GPUB ; JPO; JPO; JERW ENT; IDBM	2001/10/3 1 14:23			0



FILE ORDERING order patent files results



Wednesday 10/31/01 10:51:59 AM WFO1003PR

Serial# 60/064935 File order accepted

Place another order

FROM PALM INVENTOR NAME +

		a	Ъ	Do	Document ID	Issue Date	Pages	Title	Current OR	Current XRef
	Н			US B1	6177401	20010123	57	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and	514/1	;;;4 3 54 5
	2			US A	6004967	19991221	14		514/259	
	ω			US A	5990141	19991123	5 5	Treatment of platelet derived growth factor related disorders such as	514/378	514/5
IN SPO	42			US A	5958959	19990928	55	Treatment of platelet derived growth factor related disorders such as	514/378	514/
AUTIWNS	ъ			US A	5942385	19990824	1	molecular of tumor is and	435/4	435/ 435/ 433/ 533
v	O			US A	5932602	19990803	57	Treatment of platelet derived growth factor related disorders such as	514/380	514/3 ; 514 ; 514
	7			US	5789427	19980804	41	cancers Methods and compositions for inhibiting cell proliferative disorders	514/352	514/3 ; 546 ; 546
						***************************************		***************************************		***************************************

7	თ	U	4	ω	2	р	
Chen, Hui , et al.	Hirth, Klaus Peter , et al.	Hirth, Klaus Peter	Hirth, Klaus Peter , et al.	Hirth, Klaus Peter , et al.	McMahon, Gerald , et al.	Ullrich, Axel , et al.	Inventor
Ø	⊠	⊠	⊠	⊠	⊠	⊠	S
							၁
							đ
							2
							ω
							4
							ъ

	ω	ω	10	
G				
н				
Document ID	US 5773476 A	US 5763198 A	US 5700823 A	US 5700822
Issue Date	19980630	19980609	19971223	10011000
Pages	39	12	40	.უ დ
Title	Methods and compositions for inhibiting cell proliferative disorders	Screening assays for compounds	Treatment of platelet derived growth factor related disorders such as	Treatment of platelet derived growth factor related disorders such
Current OR	514/620	435/7.21	514/380	514/380
Curre	514/618 ; 514/619 ; 564/162 ; 564/164 ; 564/167 ; 564/168 ; 564/170	435/15 ; 435/21 ; 435/29 ; 435/7.23 ; 435/7.24 ; 435/7.94 ; 436/518 ; 436/548	514/378 ; 514/379 ; 514/521	514/379
Retrieval Classif				

Hirth, K	10 Hirth, K	9 Hirth, K., et al.	8 Chen, Hui	H
Klaus Peter	Klaus Peter	Klaus Peter	· tu	Inventor
Ø	Ø	⊠	⊠	လ
				C
				Ą
				2
				3
				4
			0	5